Background: Preterm birth defined as birth before 37 weeks of gestation is a significant public health issue. Identification of patients at risk of preterm labour while ruling out those who are not is a fundamental but challenging goal for clinicians. This study was done to evaluate bed side dipstick test for detecting fetal fibronectin in cervico-vaginal secretions as a predictor of preterm delivery in symptomatic and asymptomatic high risk group.Methods: This was a hospital based prospective, double blinded study. We enrolled 100 pregnant women presenting with or without symptoms of preterm delivery, between 20 and 35 weeks of gestation. A rapid bed side dipstick test was performed to detect FFN in cervico-vaginal secretions of all enroll...
Preterm delivery is the leading cause of neonatal mortality. One of the best predictors to assess th...
INTRODUCTION: The aim of the QUIDS study is to develop a decision support tool for the management of...
Aim: To evaluate the clinical application of the new Hologic quantitative foetal fibronectin (qfFN) ...
Background: Recently new markers like fetal fibronectin (FFN) and phosphorylated Insulin like growth...
Background: Premature birth is defined as birth of before 37 completed weeks' gestation. Not all pre...
Context: Preterm births occur in 11% of all births worldwide, but account for more than 85% of perin...
Original article can be found at : http://www.intermid.co.uk/ Copyright Mark Allen HealthcareThis pa...
Objective: This study was conducted to evaluate the usefulness of testing for fetal fibronectin (fFN...
Objective To determine whether the quantitative value of fetal fibronectin (fFN) can predict preterm...
Accurate prediction of preterm birth is a big clinical challenge in obstetrics. Most of the women pr...
Objectives: Spontaneous preterm birth is a leading cause of neonatal death. Fetal fibronectin (fFN) ...
Spontaneous preterm birth prior to 37 weeks gestation is a leading cause of neonatal morbidity and m...
Objective: To assess the cervicovaginal fetal fibronectin test to predict preterm delivery. Data Sou...
OBJECTIVE: To evaluate diagnostic accuracy of quantitative fetal fibronectin (qfFN) test in predic...
To evaluate diagnostic accuracy of quantitative fetal fibronectin (qfFN) test in predicting preterm ...
Preterm delivery is the leading cause of neonatal mortality. One of the best predictors to assess th...
INTRODUCTION: The aim of the QUIDS study is to develop a decision support tool for the management of...
Aim: To evaluate the clinical application of the new Hologic quantitative foetal fibronectin (qfFN) ...
Background: Recently new markers like fetal fibronectin (FFN) and phosphorylated Insulin like growth...
Background: Premature birth is defined as birth of before 37 completed weeks' gestation. Not all pre...
Context: Preterm births occur in 11% of all births worldwide, but account for more than 85% of perin...
Original article can be found at : http://www.intermid.co.uk/ Copyright Mark Allen HealthcareThis pa...
Objective: This study was conducted to evaluate the usefulness of testing for fetal fibronectin (fFN...
Objective To determine whether the quantitative value of fetal fibronectin (fFN) can predict preterm...
Accurate prediction of preterm birth is a big clinical challenge in obstetrics. Most of the women pr...
Objectives: Spontaneous preterm birth is a leading cause of neonatal death. Fetal fibronectin (fFN) ...
Spontaneous preterm birth prior to 37 weeks gestation is a leading cause of neonatal morbidity and m...
Objective: To assess the cervicovaginal fetal fibronectin test to predict preterm delivery. Data Sou...
OBJECTIVE: To evaluate diagnostic accuracy of quantitative fetal fibronectin (qfFN) test in predic...
To evaluate diagnostic accuracy of quantitative fetal fibronectin (qfFN) test in predicting preterm ...
Preterm delivery is the leading cause of neonatal mortality. One of the best predictors to assess th...
INTRODUCTION: The aim of the QUIDS study is to develop a decision support tool for the management of...
Aim: To evaluate the clinical application of the new Hologic quantitative foetal fibronectin (qfFN) ...